Catalent to invest $350m to expand US drug substance and product manufacturing site

URLhttps://www.biopharma-reporter.com/Article/2022/04
Sourcehttps://www.biopharma-reporter.com
Date Published04/22/2022
Author NameJane Byrne
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Catalent
Parent companyCatalent, Inc
Type of work Manufacturing
Reshoring category:Reshoring
Total number of jobs (added or to be added):1000
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2022
Year reshoring implemented or to be implemented:2022
Domestically, the work will be done:In-house
Capital investment ($):350
City reshored to:Bloomington
State(s) reshored to:IN
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoreddrug product fill/finish capacity, syringe filling
Find Reshoring Articles